Nimotuzumab for pediatric diffuse intrinsic pontine gliomas

Bibliography

• Langmoen IA, Lundar T, Storm-Mathisen I, Management of pediatric pontine gliomas. Childs Nerv Syst 1991;7:13-15
   PubMed Web of Science ®Google Scholar
• Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol 2006;24:1266-72
   PubMed Web of Science ®Google Scholar
• Mandell LR, Kadota R, Freeman C, There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brain stem tumors: results of a pediatric oncology group phase III trial comparing conventional vs hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 1999;43:959-64
   PubMed Web of Science ®Google Scholar
• Massimino M, Spreafico F, Biassoni V, Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol 2008;87:355-61
   PubMed Web of Science ®Google Scholar
• Wagner S, Warmuth-Metz M, Emser A, Treatment options in childhood pontine gliomas. J Neurooncol 2006;79:281-7
   PubMed Web of Science ®Google Scholar
• Frappaz D, Schell M, Thiesse P, Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro Oncol 2008;10:599-607
   PubMed Web of Science ®Google Scholar
• Hargrave D, Chuang N, Bouffet E. Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neurooncol 2008;86:313-19
   PubMed Web of Science ®Google Scholar
• Roujeau T, Machado G, Garnett MR, Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg 2007;107(1 Suppl):1-4
   PubMed Web of Science ®Google Scholar
• Angelini P, Hawkins C, Laperriere N, Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances. J Neurooncol 2011;101:75-81
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ, Hill DA, Hernan R. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem gliomas. Clin Cancer Res 2003;9:3620-4
   PubMed Web of Science ®Google Scholar
• Zarghooni M, Bartels U, Lee E, Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 2010;28:1337-44
   PubMed Web of Science ®Google Scholar
• Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol 2008;47:9-19
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Hau SW, Kim TY, Hwang PG, Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501
   PubMed Web of Science ®Google Scholar
• De RoocK W, Claes B, Bernasconi D, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet 2010;11:753-62
   PubMed Web of Science ®Google Scholar
• Lam C, Bouffet E, Bartels U. Nimotuzumab in pediatric glioma. Future Oncol 2009;5:1349-61
   PubMed Web of Science ®Google Scholar
• Mellinghof IK, Wang MY, Vivanco I, Molecular determinants of the response of glioblastoma to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24
   PubMed Web of Science ®Google Scholar
• Rich JN, Reardon DA, Peery T, Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42
   PubMed Web of Science ®Google Scholar
• Franceschi E, Cavall G, Lonardi S, Gefitinib in patienst with progressive high grade gliomas: a multicentre Phase II study by fruppo italiano cooperative di neuro-oncologia (gicno). Br J Cancer 2007;96:1047-51
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Tosini A, Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res 2008;14:957-60
   PubMed Web of Science ®Google Scholar
• Cedeno-Arias M, Rengifo CE, Batista YR, Immunohistochemical evaluation of H-R3 a novel humanized monoclonal antibody that neutralizes the EGF-receptor. Apll Immunohistochem Mol Morphol 2007;15:213-19
   PubMed Web of Science ®Google Scholar
• Allan DG. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005;10:760-761s
   PubMed Web of Science ®Google Scholar
• Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Bio Ther 2009;9:1199-206
   PubMed Web of Science ®Google Scholar
• Dietil M. Scientifically based report on the blood-brain-barrier in malignant tumors. Expert Opinion - BBB - malignant brain tumors. BBB-09-11-16:1-9, Institute for Pathology, Charité-University Medicine Berlin
   Google Scholar
• Fichtner I, Nowak CH. Report: biodistribution of nimotuzumab in xenografetd mice. Experimental Pharmacology & Oncology, Berlin-Buch gmbh, 22 April 2010
   Google Scholar
• Crombet Ramos T, Figueredo J, Catala S, Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3. Cancer Biol Ther 2006;5:375-9
   PubMed Web of Science ®Google Scholar
• Crombet T, Torres O, Rodriguez V, Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma 2001;20:131-6
   PubMed Web of Science ®Google Scholar
• Crombet T, Torres L, Neninger E, Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 2003;26:139-48
   PubMed Web of Science ®Google Scholar
• Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 2002;101:567-75
   PubMed Web of Science ®Google Scholar
• Investigator Brochure OSAG101 [Theraloc®-hR3 (Nimotuzumab)], Version 5: 23 June 2010, Oncoscience
   Google Scholar
• Hilger R, Bach F, Strumberg D, Fleischhack G. Pharmacokinetic study of the humanized anti-EGF-receptor monoclonal antibody nimotuzumab in infant and adult patients (Abstract #211). 99th AACR Annual Meeting; 12 – 16 April 2008; San Diego, CA
   Google Scholar
• Crombet T, Torres O, Nenninger E, Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm 2001;16:93-102
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
   PubMed Web of Science ®Google Scholar
• Bode U, Buchen S, Warmuth-Metz M, Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol (ASCO Annual Meeting Proceedings) 2007;25(18S): abstract # 2006
   Google Scholar
• Suarez G, Cabanas R, Zaldivar M, Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev 2009;11:27-33
   PubMed Web of Science ®Google Scholar
• Fleischhack G, Siegler N, Zimmermann M, Concomitant therapy of nimotuzumab and standard radiotherapy for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents.14th International Symposium of Pediatric Neuro-oncology, Vienna, Austria 20 – 23 June 2010 [abstract]. Neurooncology 2010;12:ii8
   Google Scholar
• Geyer R, Stewart CF, Kokak M, A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem glioma and supratentorial malignant gliomas. Eur J Cancer 2010;46:3287-93
   PubMed Web of Science ®Google Scholar
• Geoerger B, Hargrave D, Thomas E, Innovative therapies for children with cancer pediatric phase I study of erlotinib in pediatric brainstem glioma and relapsing/refractory brain tumors Neuro-Oncol: published online: 25 October 2010, doi: 10.1093/neuonc/noq141
   Google Scholar
• Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006;7:241-8
   PubMed Web of Science ®Google Scholar
• Biassoni V, Casanova M, Spreafico F, A case of relapsing glioblastoma multiforme responding to vinorelbine. J Neurooncol 2006;80:195-201
   PubMed Web of Science ®Google Scholar
• Kuttesch JF Jr, Krailo MD, Madden T, Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study. Pediatr Blood Cancer 2009;53:590-3
   PubMed Web of Science ®Google Scholar
• Crino L, Cappuzzo F, Zatloukal P, Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, Phase II study. J Clin Oncol 2008;26:4253-60
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
   PubMed Web of Science ®Google Scholar
• Jalali R, Raut N, Arora B, Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 2010;77:113-18
   PubMed Web of Science ®Google Scholar
• Sharp JR, Bouffet E, Stempak D, A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Eur J Cancer 2010;46:3271-9
   PubMed Web of Science ®Google Scholar
• Paugh BS, Qu C, Jones C, Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010;28:3061-8
   PubMed Web of Science ®Google Scholar